Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Janssen Research & Development, LLC
This trial will evaluate the effectiveness of administering an additional targeted therapy drug (daratumumab) in combination with Bortezomib, Lenalidomide and Dexamethasone for patients newly diagnosed with Multiple Myeloma and who are not planning on undergoing hematopoietic stem cell transplant. Patients eligible for this trial will receive either a combination of Daratumumab, Bortezomib, Lenalidomide, Dexamethasone or Bortezomib, Lenalidomide, Dexamethasone.